Burosumab
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
Conditions
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Trial Timeline
Jul 1, 2019 → Mar 1, 2023
NCT ID
NCT03993821About Burosumab
Burosumab is a phase 1 stage product being developed by Ultragenyx Pharmaceutical for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). The current trial status is unknown. This product is registered under clinical trial identifier NCT03993821. Target conditions include Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03993821 | Phase 1 | UNKNOWN |
| NCT03581591 | Phase 3 | Completed |
Competing Products
20 competing products in Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONTAK (denileukin difitox, DAB389IL-2) | Eisai | Approved | 85 |
| ONTAK | Eisai | Approved | 85 |
| E7777 9 mcg/kg | Eisai | Phase 3 | 77 |
| ONTAK | Eisai | Approved | 85 |
| Mogamulizumab | Kyowa Kirin | Approved | 85 |
| Mogamulizumab + Brentuximab vedotin | Kyowa Kirin | Phase 1 | 33 |
| Mogamulizumab | Kyowa Kirin | Phase 2 | 52 |
| KW-0761 + Vorinostat | Kyowa Kirin | Phase 3 | 77 |
| Enzastaurin | Eli Lilly | Phase 2 | 52 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Comparator: vorinostat | Merck | Pre-clinical | 23 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| TR701 FA | Merck | Phase 2 | 52 |
| MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Tulisokibart + Placebo | Merck | Phase 2 | 52 |
| Aspirin + Ipilimumab + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Mogamulizumab | Merck | Phase 2 | 52 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 77 |